Introduction: Pharmacological interventions, such as gabapentin, have been utilized to alleviate the symptoms of CTS, but the optimal dosage remains uncertain. This article aims to review and compare the efficacy of two different doses of gabapentin, 100 mg and 300 mg, in the treatment of carpal tunnel syndrome. The findings of this review may provide valuable insights for clinicians in selecting the appropriate dosage of gabapentin, balancing the need for pain relief with the potential for adverse effects.
Methodology: Following surgery, patients were administered their assigned study medication (100 mg gabapentin, 300 mg gabapentin, or placebo) orally, 1 hour before the procedure. The study medication was prepared by a pharmacist who was not involved in data collection or analysis. Both the patients and the investigators assessing the outcomes were blinded to the treatment assignment.
Results: Post hoc analyses using Tukey's test were conducted to assess specific between-group differences in pain scores. At 1 hour postoperative, there was no significant difference in pain scores between the three groups (p>0.05). However, starting from 2 hours postoperative and continuing at all subsequent time points, both the 100 mg and 300 mg gabapentin groups demonstrated significantly lower pain scores compared to the placebo group (p<0.001).
Conclusion: The results of this study demonstrate that both 100 mg and 300 mg doses of gabapentin are effective in reducing postoperative pain following CTS surgery. The 300 mg dose exhibited superior analgesic efficacy compared to the 100 mg dose, as evidenced by significantly lower pain scores and reduced rescue analgesia consumption.